ACRS - Aclaris Therapeutics, Inc.
| Previous Close | 15.43 |
| Open | 15.47 |
| Bid | 15.17 x 1000 |
| Ask | 19.95 x 800 |
| Day's Range | 14.91 - 15.48 |
| 52 Week Range | 14.11 - 28.62 |
| Volume | 196,205 |
| Avg. Volume | 245,717 |
| Market Cap | 469.977M |
| Beta | 1.14 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.38 |
| Earnings Date | Nov 5, 2018 - Nov 9, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 42.50 |
- GlobeNewswire•yesterday
Aclaris Therapeutics to Attend Upcoming Investor Conferences
WAYNE, Pa., Sept. 21, 2018-- Aclaris Therapeutics, Inc., a dermatologist-led biopharmaceutical company focused on identifying, developing, and commercializing innovative therapies to address significant ...
- GlobeNewswire•5 days ago
Aclaris Therapeutics to Highlight Drug Discovery Targeting the Human Kinome at 16th Annual Discovery on Target Meeting
WAYNE, Pa., Sept. 17, 2018-- Aclaris Therapeutics, Inc. announced that its subsidiary, Confluence Discovery Technologies, Inc., will present two posters at Cambridge Healthtech Institute’ s Discovery on ...
- GlobeNewswire•17 days ago
Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
WAYNE, Pa., Sept. 05, 2018-- Aclaris Therapeutics, Inc., a dermatologist-led biopharmaceutical company focused on identifying, developing, and commercializing innovative therapies to address significant ...
- GlobeNewswire•last month
Aclaris Therapeutics Announces ATI-450 (MK2 pathway Inhibitor) publication in the Journal Cancer Research
Aclaris Therapeutics, Inc. (ACRS), a dermatologist-led biopharmaceutical company focused on identifying, developing, and commercializing innovative therapies to address significant unmet needs in aesthetic and medical dermatology and immunology, today announced a publication in the journal Cancer Research. ATI-450, an investigational drug, is a selective inhibitor of p38 mitogen-activated protein kinase-activated protein kinase 2 (p38MAPK/MK2) interface and an attractive candidate for stromal-targeted therapy. Levels of p38MAPKα expressed by a tumor and the surrounding stromal cells correlate with poor prognosis.
- Thomson Reuters StreetEvents•last month
Edited Transcript of ACRS earnings conference call or presentation 3-Aug-18 12:00pm GMT
Q2 2018 Aclaris Therapeutics Inc Earnings Call
- Zacks•2 months ago
Aclaris Therapeutics (ACRS) Reports Q2 Loss, Tops Revenue Estimates
Aclaris (ACRS) delivered earnings and revenue surprises of -6.32% and 33.19%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•2 months ago
Aclaris: 2Q Earnings Snapshot
The Wayne, Pennsylvania-based company said it had a loss of $1.01 per share. The results did not meet Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research ...
- GlobeNewswire•2 months ago
Aclaris Therapeutics Reports Second Quarter 2018 Financial Results and Provides Update on Clinical and Commercial Developments
Management to Host Conference Call at 8:00 AM ET today. WAYNE, Pa., Aug. 03, 2018-- Aclaris Therapeutics, Inc., a dermatologist-led biopharmaceutical company focused on identifying, developing, and commercializing ...
- ACCESSWIRE•2 months ago
Aclaris Therapeutics, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / August 3, 2018 / Aclaris Therapeutics, Inc. (NASDAQ: ACRS ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 3, 2018 at 8:00 AM Eastern ...
- GlobeNewswire•2 months ago
Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
WAYNE, Pa., Aug. 02, 2018-- Aclaris Therapeutics, Inc., a dermatologist-led biopharmaceutical company focused on identifying, developing, and commercializing innovative therapies to address significant ...
- GlobeNewswire•2 months ago
Recent Analysis Shows Solar Capital, Aclaris Therapeutics, Fidus Investment, NetApp, RLJ Lodging Trust, and AvalonBay Communities Market Influences — Renewed Outlook, Key Drivers of Growth
NEW YORK, July 31, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Solar ...
- GlobeNewswire•2 months ago
Aclaris Therapeutics to Announce Second Quarter 2018 Financial Results on August 3, 2018
WAYNE, Pa., July 26, 2018-- Aclaris Therapeutics, Inc., a dermatologist-led biopharmaceutical company committed to identifying, developing, and commercializing innovative therapies to address significant ...
- Zacks•2 months ago
Aclaris' Alopecia Candidate Gets Fast Track Designation
The FDA grants fast track status to Aclaris' (ACRS) JAK-inhibitor, ATI-502, for the treatment of alopecia areata.
- GlobeNewswire•2 months ago
FDA grants Fast Track Designation to Aclaris Therapeutics’ Investigational JAK Inhibitor for the treatment of Alopecia Areata
The FDA’s Fast Track designation is intended to facilitate the development of new therapies for serious conditions and with the potential to address an unmet medical need. A company with an investigational medicine receiving Fast Track designation may be eligible for more frequent communications with the FDA and may receive an expedited review of the new drug application.
- Zacks•3 months ago
Aclaris Stock Up on JAK Inhibitor's Encouraging Activity
Aclaris Therapeutics (ACRS) posts positive interim data from a phase II study on its Alopecia Areata candidate, ATI-502.
- GlobeNewswire•3 months ago
Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Aclaris Therapeutics, Inc. (ACRS), a dermatologist-led biopharmaceutical company focused on identifying, developing, and commercializing innovative and differentiated therapies to address significant unmet needs in medical and aesthetic dermatology, today announced that on July 2, 2018 the Compensation Committee of Aclaris’ Board of Directors granted 2 non-qualified stock option awards to purchase an aggregate of 40,500 shares of its common stock and 5 restricted stock unit awards covering an aggregate of 17,300 shares of its common stock to 5 new employees under the Aclaris 2017 Inducement Plan. The stock options and restricted stock units were granted as inducements material to the new employees becoming employees of Aclaris in accordance with NASDAQ Listing Rule 5635(c)(4).
- GlobeNewswire•3 months ago
Aclaris Therapeutics Announces Positive Interim Data from Phase 2 study of ATI-502 (a topical JAK inhibitor) in Patients with Alopecia Areata
Aclaris Therapeutics, Inc. (ACRS), a dermatologist-led biopharmaceutical company committed to identifying, developing, and commercializing innovative therapies to address significant unmet needs in aesthetic and medical dermatology and immunology, today announced positive interim data from its Phase 2 clinical trial (AA-202 Topical) of ATI-502 for the treatment of Alopecia Totalis (AT) or Alopecia Universalis (AU), the more severe variants of Alopecia Areata (AA). ATI-502, an investigational topical Janus Kinase (JAK) 1/3 inhibitor (ATI-502) is the most advanced topical JAK inhibitor in clinical trials for AT/AU in the United States.
- GlobeNewswire•3 months ago
Aclaris Therapeutics Announces First Patient Dosed in a Phase 2 Clinical Trial of ATI-501 Oral Suspension in Patients with Alopecia Totalis and Alopecia Universalis
Aclaris Therapeutics, Inc. (ACRS), a dermatologist-led biopharmaceutical company committed to identifying, developing, and commercializing innovative therapies to address significant unmet needs in aesthetic and medical dermatology and immunology, today announced that the first patient has been dosed in Aclaris’ Phase 2 clinical trial of its JAK inhibitor product candidate ATI-501 oral suspension in patients with two forms of Alopecia Areata (AA) known as Alopecia Totalis (AT) and Alopecia Universalis (AU). AA is an autoimmune dermatologic condition typically characterized by patchy non-scarring hair loss on the scalp and body. More severe forms of AA include AT, which is total scalp hair loss, and AU, which is total hair loss on the scalp and body.
- ACCESSWIRE•4 months ago
Wired News - Aimmune Therapeutics Presents Data from New Pan-European Study on Psychosocial Burden Associated with Peanut Allergy at EAACI Congress 2018
LONDON, UK / ACCESSWIRE / June 1, 2018 / If you want access to our free research report on Aimmune Therapeutics, Inc. (NASDAQ: AIMT), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=AIMT as the Company's latest news hit the wire. On May 30, 2018, the Company announced that it presented data from a new study on the psychosocial burden of peanut allergy in European countries at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2018 in Munich. Active-Investors.com is currently working on the research report for Aclaris Therapeutics, Inc. (NASDAQ: ACRS), which also belongs to the Healthcare sector as the Company Aimmune Therapeutics.
- Benzinga•4 months ago
Cantor Fitzgerald: 18 Drug Companies With Catalysts Worth Watching
The biotech analysts at Cantor Fitzgerald have a packed calendar: here are some of the dates they’re tracking and why they’re important. Mallinckrodt PLC (NYSE: MNK ) is expected to release Phase 4 interim ...
